Table 1.
Baseline demographic and clinical characteristics
| Pt no. | Sex/ age | KPS | Tumor location | Surgery | Radiation (Gy/fr) | Chemotherapy other than TMZ | HSV-1 IgM/IgGa | Ki-67 (%) | IDH1 | MGMT promoter MSP | MGMT expression | Rec/ Res | Time from initial surgery to G47Δ (months) | Tumor area Baseline (mm2) | MET-PET L/N | Steroids | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before G47Δ | New or increased dose during G47Δ treatment | ||||||||||||||||
| 1 | M/54 | 90 | R/Fr | GTR | 50.4/28 | − | 0.23/<2.0 | 4 | wt | NA | + | 1st | 12.4 | 375.2 | 1.71 | − | − |
| 2 | M/49 | 90 | R/Fr | PR | 60/30 | − | 0.09/<2.0 | 5 | wt | NA | − | Res | 3.0 | 220.0 | 1.50 | − | − |
| 3 | F/63 | 80 | L/Fr | PR | 60/30 | − | 0.10/15.1 | 5 | wt | NA | + | Res | 3.4 | 661.4 | 3.62 | − | − |
| 4 | M/69 | 90 | L/T | GTR | 60/30 | − | 0.19/2.7 | 15 | wt | unmet | + | 1st | 8.7 | 176.9 | 1.78 | − | − |
| 5 | M/46 | 100 | R/Fr | GTR | 50.4/28 | BEV | 0.46/51.4 | 6 | wt | unmet | − | 1st | 14.1 | 554.2 | 1.95 | − | Hydrocortisone (500 mg ×1 dose, 5 times) |
| 6 | F/25 | 70 | L/P | PR | 60/30 | BEV, BCNU wafer | 0.13/<2.0 | 7 | mt | unmet | + | 2nd | 23.5 | 696.6 | 2.15 | − | − |
| 7 | M/51 | 90 | R/T | PR | 60/30 | − | 0.44/<2.0 | 40 | wt | NA | − | Res | 3.0 | 440.7 | 2.50 | − | − |
| 8 | M/73 | 70 | R/Fr | PR | 60/30 | − | 0.18/123.0 | 30 | wt | NA | + | 1st | 5.3 | 1,386.5 | 1.02 | Prednisolone 10 mg d−1 | − |
| 9 | M/46 | 100 | R/Fr | GTR | 60/30 | BCNU wafer, IFNβ | 0.18/<2.0 | 8 | wt | NA | − | 1st | 24.9 | 122.4 | 1b | − | − |
| 10 | M/28 | 100 | L/Fr | GTR | 60/30 | BEV, BCNU wafer | 0.24/<2.0 | 30–40 | mt | NA | − | 1st | 9.4 | 141.4 | 1.60 | − | − |
| 11 | M/53 | 80 | R/T | GTR | 60/30 | BCNU wafer | 0.20/<2.0 | 2 | mt | NA | − | 1st | 7.4 | 416.2 | 1.35 | − | − |
| 12 | M/59 | 70 | L/Fr | Biopsy | 60/30 | BEV | 0.31/2.3 | 40 | wt | met | − | 1st | 4.2 | 519.9 | 1.38 | − | Dexamethasone (19.8 mg d−1 to 6.6 mg d−1 ×6 d, 1 time) |
| 13 | F/53 | 70 | R/Fr | PR | 60/30 | BEV, BCNU wafer | 0.45/105.0 | 30 | mt | met | − | Res | 4.1 | 873.1 | 1.86 | − | − |
| 14 | M/42 | 80 | Splenium | PR | 60/30 | − | 0.19/<2.0 | 50 | wt | NA | + | 1st | 10.1 | 1,832.2 | 2.27 | − | Dexamethasone (19.8 mg d−1 to 13.2 mg d−1 ×4 d, 1 time); prednisolone (30 mg d−1 to 15 mg d−1 ×6 d, 1 time) |
| 15 | M/65 | 80 | L/P | Biopsy | 60/30 | BEV | 0.23/164.0 | 15 | wt | NA | + | Res | 4.4 | 652.8 | 1.54 | − | Betamethasone (24 mg d−1 to 6 mg d−1 ×6 d, 1 time) |
| 16 | M/45 | 100 | R/Fr | PR | 60/30 | BCNU wafer | 0.10/<2.0 | 50 | mt | NA | − | Res | 3.1 | 2,306.7 | 2.64 | − | − |
| 17 | M/68 | 90 | R/T | PR | 60/30 | − | 0.18/220.0 | 20 | wt | NA | + | Res | 3.9 | 291.5 | 2.39 | − | − |
| 18 | F/43 | 80 | L/P | Biopsy | 60/30 | BEV | 0.30/216.0 | 10 | wt | NA | − | Res | 3.8 | 513.5 | 2.01 | − | Prednisolone (30 mg d−1 ×7 d, 1 time) |
| 19 | M/35 | 80 | R/Fr | PR | 59.4/33 | − | 0.14/<2.0 | 90 | mt | NA | − | Res | 3.6 | 778.5 | 1.27 | − | − |
Abbreviations: F, female; M, male; KPS, Karnofsky Performance Scale; R, right; L, left; Fr, frontal lobe; T, temporal lobe; P, parietal lobe; GTR, gross total resection; PR, partial resection; TMZ, temozolomide; BEV, bevacizumab; BCNU wafer, carmustine wafer; IFNβ, interferon-β; HSV-1, herpes simplex virus type 1; IDH1, isocitrate dehydrogenase 1; mt, mutant type; wt, wild type; MGMT, methylguanine methyltransferase; MSP, methylation-specific PCR; met, methylated; unmet, unmethylated; NA, not available; Rec, recurrent; Res, residual; 1st, first recurrence; 2nd, second recurrence; MET, methionine; PET, positron emission tomography; L/N, lesion-to-normal ratio.
a1 d before first therapy.
bL/N could not be measured, because there was no increased uptake corresponding to the target lesion.
GTR is defined as >95% of the tumor removed assessed by the surgeon. Resection other than GTR is either PR or biopsy as judged by the surgeon.
Immunohistochemistry for MGMT expression: –, <10%; +, ≥10% and <50%; ++, ≥50%.